Bruno R. Bastos, MD, Miami Cancer Institute
Articles by Bruno R. Bastos, MD, Miami Cancer Institute
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.
Renal Cell Carcinoma: Future Evolutions in Care
ByBrian I. Rini, MD, Cleveland Clinic,Eric Jonasch, MD, University of Texas MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie Berg, DO Shared insight on the evolving state of renal cell carcinoma management and hope for future growth in the treatment landscape.
Selecting Optimal Therapy for Advanced Non-Clear Cell RCC
ByDiscussant: Brian I. Rini, MD, Cleveland Clinic,Eric Jonasch, MD, University of Texas MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie Berg, DO Focusing their discussion on a real-world patient scenario, expert panelists discuss treatment options in the setting of advanced non-clear cell renal cell carcinoma.
Relapsed/Refractory Clear Cell RCC: Novel Treatment Strategies
ByBrian I. Rini, MD,Eric A. Jonasch, MD, MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie Berg, DO Switching their focus to relapsed/refractory advanced clear cell renal cell carcinoma, key opinion leaders review treatment options in this setting.
Second-Line Treatment Armamentarium in Clear Cell RCC
ByBrian I. Rini, MD,Eric A. Jonasch, MD, MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie Berg, DO Comprehensive insight to treatment options available in the second-line setting of advanced clear cell renal cell carcinoma.
Rationale Behind Discontinuing IO Therapy in Clear Cell RCC
ByBrian I. Rini, MD,Eric A. Jonasch, MD, MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie Berg, DO Focused discussion on the rationale behind discontinuing (or continuing) immunotherapy for patients with advanced clear cell renal cell carcinoma.
Selecting Therapy for a Real-World Patient With Clear Cell RCC
ByBrian I. Rini, MD,Eric A. Jonasch, MD, MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie Berg, DO Centering discussion on a patient scenario of advanced clear cell renal cell carcinoma, panelists reflect on how they would approach selecting first-line therapy.
Dosing Strategies With First-Line Therapy in Advanced Clear Cell RCC
ByBrian I. Rini, MD,Eric Jonasch, MD, University of Texas MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie Berg, DO Panelists consider best practices in dosing while managing patients on first-line therapy for advanced clear cell renal cell carcinoma.
Advanced Clear Cell RCC: AE Profile of First-Line Combination Therapies
ByBrian I. Rini, MD, Cleveland Clinic,Eric Jonasch, MD, University of Texas MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie Berg, DO Expert perspectives on the adverse event profiles of first-line combination therapies in the advanced clear cell renal cell carcinoma space.
Factors in Selecting First-Line Therapy for Patients With Advanced Clear Cell RCC
ByBrian I. Rini, MD,Eric Jonasch, MD, University of Texas MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Bruno R. Bastos, MD, Miami Cancer Institute ,Stephanie Berg, DO A brief discussion on the patient and disease characteristics that help to inform selection of best therapy for patients with advanced clear cell renal cell carcinoma.
Overview of First-Line Combination Therapy in Advanced Clear Cell RCC
ByBrian I. Rini, MD,Eric Jonasch, MD, University of Texas MD Anderson Cancer Center,Elizabeth R. Plimack, MD, MS, Fox Chase Cancer Center,Stephanie Berg, DO,Bruno R. Bastos, MD, Miami Cancer Institute Key opinion leaders on renal cell carcinoma management review first-line treatment options in the advanced clear cell disease space.
